Analysis of an unusual cluster of systemic reactions to subcutaneous specific immunotherapy with respiratory allergens in one allergy center by Scherer, K. et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Short Communication 
 Int Arch Allergy Immunol 2012;157:318–320 
 DOI: 10.1159/000328753 
 Analysis of an Unusual Cluster of Systemic 
Reactions to Subcutaneous Specific 
Immunotherapy with Respiratory Allergens
in One Allergy Center 
 Kathrin Scherer a    Christian Schindler b    Andreas Arnold a    Silvy Bach a    
Andreas J. Bircher a  
 a  Allergy Unit, Department of Dermatology, University Hospital Basel, and  b  Swiss Tropical and Public Health Institute, 
 Basel , Switzerland 
on the allergen type and extracts, the type of immuno-
therapy (standard vs. cluster vs. rush) and induction ver-
sus maintenance phase  [3, 4] . Retrospectively, they range 
from 0.01 to 0.37%  [5, 6] , prospectively, around 0.1%  [7] 
of injections. The rate of SR per patient varies from 1.1 to 
7.4  [5, 8] , and most are grade I and II reactions.
 In our allergy unit, SCIT is routinely performed. Ap-
proximately 120–160 patients per year are regularly start-
ed with respiratory allergens by standard and cluster reg-
imens. Experienced nurse staff prepares the extract solu-
tions and allergists perform the injections. Patients are 
surveyed for at least 30 min. If SR are encountered they 
are treated immediately.
 In 2004, we treated 158 patients and we observed a to-
tal of 11 SR in 10 patients (6.32% of patients, 8 females, 
mean age 32 years, range 18–71; 8 patients had preexist-
ing, currently well-controlled asthma). A cluster of 8 SR 
occurred in the last quarter; 5 patients suffered from 6 
reactions within a period of 6 weeks. Seven of 11 SR oc-
curred to Novo-Helisen  (Allergopharma, Reinbek, Ger-
many), 3 to Alutard SQ  (ALK Denmark) and 1 to an 
Allergovit  (Allergopharma) preparation. Eight of the 10 
patients were treated with 2 different extracts, 2 patients 
with 1 extract each. One patient with 2 extracts had 2 SR. 
All SR occurred within 30 min after the injection. The 
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 Abstract 
 Systemic reactions to subcutaneous immunotherapy occur 
despite all necessary precautions and experienced staff and 
should prompt a search for causative factors. We present an 
analysis of 11 reactions, 8 of them within a short period. The 
patients and reactions were evaluated regarding extract 
 errors (composition, concentration), dosing errors, ignored 
contraindications to specific subcutaneous immunotherapy, 
introductions versus maintenance phase and accidental in-
travascular injection. No single or common cause could be 
identified. Statistical analysis suggests that exceptional clus-
ters of systemic reactions such as these may be just random 
cumulations without identifiable cause. 
 Copyright © 2011 S. Karger AG, Basel 
 Specific subcutaneous immunotherapy (SCIT) with 
respiratory allergens is well established. However, local as 
well as systemic reactions (SR) and, in rare cases, fatalities 
 [1, 2] are possible. Rates of non-fatal SR vary, depending 
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reactions were graded according to H.L. Mueller: 2 grade 
I, 3 grade II, 5 grade III and 1 grade IV. One patient suf-
fered from a grade II and a grade III reaction within 1 
month ( table 1 ). Treatment included inhaled and intra-
muscular epinephrine, intravenous clemastine and meth-
ylprednisolone, with a beneficial response in all. All cas-
es were reported to the pharmacovigilance and docu-
mented as critical incidence reports.
 We retrospectively identified all patients who had re-
ceived specific immunotherapy with respiratory aller-
gens, the products used and the number of injections giv-
en. In 2004, 158 patients with rhinoconjunctivitis and/or 
asthma received a total of 1,630 allergen doses of Novo-
Helisen (Allergopharma) ( table 1 ), 559 doses of Alutard 
SQ (ALK Denmark) and 300 doses of Allergovit (Aller-
gopharma). A total of 20 extracts was administered to 10 
patients before the 11 SR. The calculated incidence of SR 
was 6.3% in the patients, and the respective proportions 
in the preparations were: in 6 patients, Novo-Helisen 
14/1,630 doses (0.0066%), in 3 patients, Alutard SQ 4/559 
doses (0.007%), and in 1 patient Allergovit 1/300 doses 
(0.0033%).
 The patients and reactions were evaluated with re-
gard to the following risk factors: (1) extract error (com-
position, concentration), (2) dosing errors, (3) ignored 
contraindications (symptoms to allergen exposure, un-
controlled asthma, intercurrent infections, interfering 
drugs), (4) introduction versus maintenance phase, and 
(5) accidental intravascular injection.
 No errors with regard to extract selection or dosing 
could be identified. Injections were given subcutaneously 
on the lateral upper arm after careful aspiration. The 6 
patients who had received Novo-Helisen preparations 
were further analyzed. The administered preparations 
were sent back to the company and analyzed with regard 
to allergen content. All solutions contained the respective 
allergens in correct concentrations. All 10 patients con-
tinued SCIT up to a complete 3-year course without fur-
ther SR.
 A logistic regression analysis was performed to assess 
the statistical significance of the incidence rates between 
the last 4 weeks of 2004 as compared to the rest of the 
year. Five of the 11 cases occurred during these last 4 
weeks of 2004. The analysis was adjusted for potential 
heterogeneity of susceptibility between subjects and pro-
vided a p value of 0.0002. To test the hypothesis that non-
random clustering occurs in at least 1 of the 52 possible 
4-week periods against the null-hypothesis of side effects 
occurring independently of each other and without any 
association with calendar time, this p value would have 
to be multiplied by 52 (Bonferroni adjustment). There-
fore, an adjusted p value of 0.01 might be appropriate. In 
addition, we conducted a simulation analysis in which we 
randomly distributed the 11 events across all sessions of 
the year. As a measure of heterogeneity, we considered the 
variance of successive distances between events. These 
distances were defined as the number of sessions between 
consecutive events augmented by 1. Closing the ‘string’ of 
Table 1.  Number of sessions, allergen extracts and doses per quarter in 2004
1. quarter 2. quarter 3. quarter 4. quarter Total
Sessions, n 287 374 301 596 1,444 (100%)
Allergovit doses 115 50 0 135 300
Alutard SQ doses 162 182 167 247 559
Novo-Helisen doses 406 303 322 599 1,630 (85.5%)
Grades of AR Patients with AR
Allergovit 0 0 0 I 1
Alutard SQ
Induction 0 0 0 II 1
Maintenance 0 III III 0 2
Novo-Helisen
Induction 0 0 II, III, IV 3
Maintenance II 0 I, III, III 4
Total adverse reactions 2 1 8 11
AR = Adverse reactions; I = AR grade I; II = AR grade II; III = AR grade III; IV = AR grade IV.
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sessions to a ‘necklace’ enabled the determination of an 
11th distance. In less than 10 out of 10,000 randomly gen-
erated distributions, the respective variance was higher 
than the one observed in our data, suggesting that there 
was even less visible clustering. In summary, the higher 
incidence of severe allergic reactions observed in the 4th 
quarter of 2004, and more specifically during the last 
month of 2004, can be explained as a rare clustering of 
random events.
 In  table 1 , the overview of the 4 quarters of 2004 with 
the number of subcutaneous injections of allergen ex-
tracts, the number of sessions and the number of the 3 
different preparations used is given.
 Novo-Helisen was the most frequently administered 
extract (85.5%) with a rate of 7 adverse SR among 1,630 
administered doses (0.0066%). There was no statistical 
significance with regard to other preparations and no dif-
ference between induction and maintenance doses. We 
further analyzed possible causes of SR to this extract. 
Neither composition nor dilution or dosing errors nor ig-
nored contraindications could be identified. Since most 
reactions occurred outside of the pollen season, this fac-
tor is most likely not relevant  [9] . Having excluded – as 
far as possible – all known causes for SR  [10, 11] and hav-
ing assured a proper subcutaneous injection technique, 
we suppose that the question of where the allergen is de-
posited in the subcutaneous tissue in relation to blood 
vessels in particular might be of relevance with regard to 
the speed of systemic distribution of the allergen. How-
ever, there are no hard data on this issue. For the cluster 
of SR in 2004, we suppose that most likely, paravascular 
injections were responsible for the SR, which began most 
often within a few minutes after the injection.
 According to our estimates, the risk of observing a 
comparable clustering in a given year just by chance is 
 ! 1% in our setting. In the following year 2005, 4.6% of 
patients (as compared to 6.32% in 2004) suffered SR dur-
ing SCIT. Exact rates per injection were not calculated.
 In conclusion, we have seen comparable rates of SR in 
SCIT as reported in the literature  [5] . Particular risk fac-
tors such as uncontrolled asthma, cluster treatment or 
allergen extracts from a particular manufacturer  [12–14] 
were not present. Mix-up of extracts or wrong doses could 
not be identified. Also, other patient- or physician-related 
mistakes were not present. Severe allergic reactions occur 
rarely upon SCIT, and even in a well-controlled, experi-
enced setting, their onset is possible at any time. How-
ever, the cluster we observed is a very rare event.
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